Skip to main content

KALA BIO, Inc.

corporate_fare Company Profile

KALA BIO, Inc.

KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company's lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical development product consists of KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed KALA - Latest Insights

KALA
Apr 15, 2026, 4:05 PM EDT
Source: Wiseek News
Importance Score:
9
KALA
Apr 15, 2026, 4:03 PM EDT
Filing Type: 10-K
Importance Score:
9
KALA
Mar 04, 2026, 9:16 AM EST
Filing Type: 8-K
Importance Score:
9
KALA
Feb 20, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
8
KALA
Feb 17, 2026, 4:44 PM EST
Filing Type: 424B3
Importance Score:
9
KALA
Feb 09, 2026, 5:45 PM EST
Filing Type: S-3
Importance Score:
9
KALA
Feb 06, 2026, 4:14 PM EST
Filing Type: SCHEDULE 13D
Importance Score:
8
KALA
Feb 05, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
8
KALA
Feb 02, 2026, 6:01 AM EST
Filing Type: 8-K
Importance Score:
9
KALA
Jan 23, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
9
KALA
Jan 08, 2026, 4:07 PM EST
Filing Type: 8-K
Importance Score:
8
KALA
Jan 08, 2026, 4:05 PM EST
Filing Type: 424B5
Importance Score:
9
KALA
Jan 06, 2026, 4:05 PM EST
Filing Type: DEFA14A
Importance Score:
8
KALA
Jan 06, 2026, 7:31 AM EST
Filing Type: 8-K
Importance Score:
8
KALA
Jan 02, 2026, 4:16 PM EST
Filing Type: 8-K
Importance Score:
9